OTCMKTS:NEPHNephros Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Nephros, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $8.05 -0.02 (-0.25 %) (As of 07/3/2020 04:00 PM ET) Add Compare Share Today's Range$7.90Now: $8.05▼$8.1350-Day Range$7.07MA: $7.94▼$8.5652-Week Range$4.42Now: $8.05▼$11.35Volume2,801 shsAverage Volume14,534 shsMarket Capitalization$72.51 millionP/E RatioN/ADividend YieldN/ABeta0.85 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Nephros, Inc., a commercial stage medical device and commercial product company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems primarily in the United States. It operates through two segments, Water Filtration and Renal Products. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from water borne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It offers HDF systems for use in conjunction with a hemodialysis machine that enables nephrologists to provide HDF treatment to patients with end stage renal disease; hemodiafilters for use as dialyzers in hemodialysis treatment; and water filters to food service, hospitality, and convenience store markets under the AETHER brand name. The company was founded in 1997 and is headquartered in South Orange, New Jersey.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingNephros has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.00, Nephros has a potential upside of 98.8% from its current price of $8.05.Amount of Analyst CoverageNephros has received no research coverage in the past 90 days. Previous Next 2.0 Community Rank Outperform VotesNephros has received 70 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNephros has received 109 “underperform” votes. (Add your “underperform” vote.)Community SentimentNephros has received 60.89% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Nephros and other stocks. Vote “Outperform” if you believe NEPH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NEPH will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNephros does not currently pay a dividend.Dividend GrowthNephros does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nephros insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,800.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 6.80% of the stock of Nephros is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Nephros are expected to grow in the coming year, from ($0.63) to ($0.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nephros is -14.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nephros is -14.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNephros has a P/B Ratio of 9.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.83 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:NEPH Previous SymbolNASDAQ:NEPH CUSIPN/A CIK1196298 Webwww.nephros.com Phone201-343-5202Debt Debt-to-Equity Ratio0.26 Current Ratio2.56 Quick Ratio1.86Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$5.69 million Price / Sales12.74 Cash FlowN/A Price / Cash FlowN/A Book Value$0.89 per share Price / Book9.04Profitability EPS (Most Recent Fiscal Year)($0.54) Net Income$-3,400,000.00 Net Margins-49.93% Return on Equity-56.37% Return on Assets-35.17%Miscellaneous Employees18 Outstanding Shares9,007,000Market Cap$72.51 million Next Earnings DateN/A OptionableNot Optionable OTC:NEPH Rates by TradingView Receive NEPH News and Ratings via Email Sign-up to receive the latest news and ratings for NEPH and its competitors with MarketBeat's FREE daily newsletter. Nephros (OTCMKTS:NEPH) Frequently Asked Questions How has Nephros' stock been impacted by COVID-19 (Coronavirus)? Nephros' stock was trading at $7.47 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NEPH stock has increased by 7.8% and is now trading at $8.05. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Nephros? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nephros in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Nephros. How were Nephros' earnings last quarter? Nephros, Inc. (OTCMKTS:NEPH) released its quarterly earnings results on Wednesday, May, 6th. The company reported ($0.13) EPS for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.04. The company had revenue of $2.53 million for the quarter. Nephros had a negative net margin of 49.93% and a negative return on equity of 56.37%. View Nephros' earnings history. What price target have analysts set for NEPH? 2 brokers have issued 1 year price targets for Nephros' stock. Their forecasts range from $16.00 to $16.00. On average, they expect Nephros' stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 98.8% from the stock's current price. View analysts' price targets for Nephros. Has Nephros been receiving favorable news coverage? Headlines about NEPH stock have trended negative recently, InfoTrie reports. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Nephros earned a coverage optimism score of -2.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Nephros. Who are some of Nephros' key competitors? Some companies that are related to Nephros include Iradimed (IRMD), SeaSpine (SPNE), iCAD (ICAD), Westaim (WEDXF), Liquidia Technologies (LQDA), Pulse Biosciences (PLSE), Accuray (ARAY), Apyx Medical (APYX), RenovaCare (RCAR), T2 Biosystems (TTOO), TELA Bio (TELA), Soliton (SOLY), Restoration Robotics (HAIR), BeyondAirInc . (XAIR) and Venus Concept (VERO). View all competitors. What other stocks do shareholders of Nephros own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nephros investors own include Cytosorbents (CTSO), Iovance Biotherapeutics (IOVA), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), AbbVie (ABBV), Allena Pharmaceuticals (ALNA), BIOLINERX LTD/S (BLRX), Energy Transfer LP Unit (ET), Rigel Pharmaceuticals (RIGL) and Verastem (VSTM). Who are Nephros' key executives? Nephros' management team includes the following people: Mr. Daron G. Evans, Pres, CEO & Director (Age 45)Mr. Andrew Astor, CFO & COO (Age 62)Ms. Joleen C. Turner, VP of Marketing & Bus. Devel. What is Nephros' stock symbol? Nephros trades on the OTCMKTS under the ticker symbol "NEPH." How do I buy shares of Nephros? Shares of NEPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Nephros' stock price today? One share of NEPH stock can currently be purchased for approximately $8.05. How big of a company is Nephros? Nephros has a market capitalization of $72.51 million and generates $5.69 million in revenue each year. The company earns $-3,400,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. Nephros employs 18 workers across the globe. What is Nephros' official website? The official website for Nephros is www.nephros.com. How can I contact Nephros? Nephros' mailing address is 380 LACKAWANNA PLACE, SOUTH ORANGE NJ, 07079. The company can be reached via phone at 201-343-5202. This page was last updated on 7/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
